Articles > Popular publications > PR Newswire press releases > July-September 2007 > Wednesday, September 19

Article: ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes.

Article from:
PR Newswire
Article date:
September 19, 2007
Copyright

Results presented at the 43rd European Association for the Study of Diabetes Annual Meeting

AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS(R) (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type 2 diabetes belonging to the thiazolidinedione (TZD) class of drugs.

Study Design and Results (PS130 / Abstract #1257)

This retrospective analysis of case records from a large managed care database of patients with ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: Takeda Pharmaceuticals North America Initiates ...

  
  PR Newswire; 
  April 1, 2003 ;  
  
  
 
  700+ words
... ... Takeda Pharmaceuticals North America (TPNA) announced the ... investigate the effect of ACTOS(R) (pioglitazone ... Some people taking ACTOS may experience cold ... trials. When taking ACTOS with insulin or sulfonylureas ... Takeda Pharmaceuticals North America, Inc. Based in  ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Improved Web Site Encourages Patients to Take Action.(Takeda ...

  
  Diabetes Week; 
  December 17, 2001 ;  
  
  
 
  700+ words
... ... Takeda Pharmaceuticals North America, Inc., and Eli ... with the upgrade of ACTOS.com. This resource ... management plans. ACTOS (pioglitazone HCl ... Takeda Pharmaceuticals North America, Inc., "By improving ACTOS.com, Takeda and ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Takeda's Actos combats diabetic atherosclerosis.(Takeda ...

  
  Pharma Marketletter; 
  November 20, 2006 ;  
  
  
 
  700+ words
...Takeda Pharmaceutical North America, a wholly-owned subsidiary ... that new trial data shows that Actos (pioglitazone HCl), its ... was primarily a comparison of Actos with the sulfonylurea drug ... of the results revealed that Actos conferred a statistically ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Takeda defends Actos.(RX RETAIL PHARMACY: ...

  
  Chain Drug Review; 
  August 20, 2007 ;  
  
  
 
  515 words
...Takeda Pharmaceuticals North America Inc. has reaffirmed the safety of Actos, its diabetes treatment. The Deerfield, III.-based company presented testimony before an FDA advisory committee.







   
 




  




 

    

 
 
   
 


   
  
  Article: 25 Million ACTOS(R) Prescriptions Translates to Millions ...

  
  PR Newswire; 
  August 25, 2003 ;  
  
  
 
  700+ words
... ... large number of patients ACTOS has helped to manage ... Takeda Pharmaceuticals North America (TPNA). "We're very proud of what ACTOS has achieved in a short ... Takeda Pharmaceuticals North America, Inc. and Eli Lilly ... com/ http://www.actos.com/ http://www ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: New Data Published in Circulation Showed an Increase in HDL ...

  
  PR Newswire; 
  April 15, 2008 ;  
  
  
 
  700+ words
... ... experienced visual changes while taking ACTOS. Please visit the ACTOS Web site at http://www.actos.com/ for Complete Prescribing Information. Takeda Pharmaceuticals North America, Inc. Based in Deerfield, Ill., Takeda ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Data Presented at the American Heart Association Scientific ...

  
  PR Newswire; 
  November 6, 2007 ;  
  
  
 
  700+ words
... ... experienced visual changes while taking ACTOS. Please visit the ACTOS Web site at http://www.actos.com/ for Complete Prescribing Information. Takeda Pharmaceuticals North America, Inc. Based in Deerfield, Ill., Takeda ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: ACTOS(R) (pioglitazone HCl) To Be Studied In New Trial ...

  
  PR Newswire; 
  June 9, 2006 ;  
  
  
 
  700+ words
... ... science suggesting that ACTOS may have benefits beyond ... Takeda Pharmaceuticals North America, Inc. "CHICAGO will ... cardiovascular studies with ACTOS: the PROactive study ... anemia. When taking ACTOS with insulin or sulfonylureas ... Takeda Pharmaceuticals North America, Inc.  ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives